Cardiovascular magnetic resonance and the evaluation of heart failure

Current Cardiology Reports

Volumn 7, Issue 1, 2005, Pages 39-44

  Moon, James C C ^a   Prasad, Sanjay K ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEFEROXAMINE; DOBUTAMINE; GADOLINIUM; GADOLINIUM PENTETATE; IRON;

CELL VIABILITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART MUSCLE PERFUSION; HEART VOLUME; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERMETHOD COMPARISON; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; IRON OVERLOAD; MAGNETIC RESONANCE ANGIOGRAPHY; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; THALASSEMIA MAJOR; TISSUE CHARACTERIZATION;

EID: 13544265649     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-005-0009-3     Document Type: Review

References (50)

1. Kramer CM: Integrated approach to ischemic heart disease The one-stop shop. Cardiol Clin 1998, 16:267-276.
2. Choudhury L, Mahrholdt H, Wagner A: Myocardial scarring in minimally symptomatic patients with hypertrophic cardiomyopathy [abstract]. Circulation 2001, 104:756.
3. Panting JR, Gatehouse PD, Yang GZ, et al.: Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002, 346: 948-1953.
4. Anderson LJ, Holden S, Davis B, Prescott E, et al.: Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001, 22: 171-2179.
5. Yuan C, Zhang SX, Polissar NL, et al.: Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 2002, 105:181-185.
6. Cortil R, Badimonl J, Mizsei G, et al.: Real-time MR-guided endomyocardial local delivery. Heart 2004, in press.
7. Bellenger NG, Burgess MI, Ray SG, et al.: Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 2000, 21:1387-1396.
8. Moon JC, Lorenz CH, Francis JM, et al.: Breath-hold FLASH and FISP cardiovascular MR imaging: left ventricular volume differences and reproducibility. Radiology 2002, 223: 89-797.
9. Grothues F, Smith GC, Moon JC, et al.: Comparison of inter-study reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002, 90:29-34.
10. Nagel E, Lehmkuhl HB, Bocksch W, et al.: Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation 1999, 99:763-770.
11. Hundley WG, Morgan TM, Neagle CM, et al.: Magnetic resonance imaging determination of cardiac prognosis. Circulation 2002, 106:2328-2333.
12. Bogaert J, Maes A, Van de WF, et al.: Functional recovery of subepicardial myocardial tissue in transmural myocardial infarction after successful reperfusion: an important contribution to the improvement of regional and global left ventricular function. Circulation 1999, 99:36-43.
13. Simonetti OP, Kim RJ, Fieno DS, et al.: An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001, 218:215-223.
14. Beek AM, Kuhl HP, Bondarenko O, et al.: Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol 2003, 42:895-901.
15. Kim RJ, Wu E, Rafael A, Chen EL, et al.: The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000, 343:1445-1453.
16. Bello D, Shah DJ, Farah GM, et al.: Gadolinium, cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003, 108:1945-1953.
17. Ricciardi MJ, Wu E, Davidson CJ, et al.: Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001, 103:2780-2783.
18. Fieno DS, Hillenbrand HB, Rehwald WG, et al.: Infarct resorption, compensatory hypertrophy, and differing patterns of ventricular remodeling following myocardial infarctions of varying size. J Am Coll Cardiol 2004, 43:2124-2131.
19. Selvanayagam JB, Petersen SE, Francis JM, et al.: Effects of off-pump versus on-pump coronary surgery on reversible and irreversible myocardial injury: a randomized trial using cardiovascular magnetic resonance imaging and biochemical markers. Circulation 2004, 109:345-350.
20. Barkhausen J, Hunold P, Jochims M, et al.: Imaging of myocardial perfusion with magnetic resonance. J Magn Reson Imaging 2004, 19:750-757.
21. Arai AE: Magnetic resonance first-pass myocardial perfusion imaging. Top Magn Reson Imaging 2000, 11: 83-398.
22. Lee DC, Simonetti OP, Harris KR, et al.: Magnetic resonance versus radionuclide pharmacological stress perfusion imaging for flow-limiting stenoses of varying severity. Circulation 2004, 110:58-65.
23. Sipola P, Lauerma K, Husso-Saastamoinen M, et al.: First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. Radiology 2003, 226:129-137.
24. Hunold P, Maderwald S, Eggebrecht H, et al.: Steady-state free precession sequences in myocardial first-pass perfusion MR imaging: comparison with TurboFLASH imaging. Eur Radiol 2004, 14:409-416.
25. Elkingtion AG, Gatehouse PD, Cannell TM, et al.: Comparison of Hybrid EPI and FLASH Myocardial Perfusion CMR. Radiology 2004, in press.
26. Mogensen J, Murphy RT, Kubo T, et al.: Prevalence and clinical characteristics of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy: implications for management, counseling and follow-up. J Am Coll Cardiol 2004, in press.
27. Moon JC, Fisher NG, McKenna WJ, et al.: Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004, 90:645-649.
28. Paelinck BP, Lamb HJ, Bax JJ, et al.: Assessment of diastolic function by cardiovascular magnetic resonance. Am Heart J 2002, 144:198-205.
29. Redwood CS, J.C., Watkins H: Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999, 44:20-36.
30. Nakae I, Mitsunami K, Omura T, et al.: Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol 2003, 42:1587-1593.
31. Schulz-Menger J, Gross M, Messroghli D, et al.: Cardiovascular magnetic resonance of acute myocardial infarction at a very early stage. J Am Coll Cardiol 2003, 42:513-518.
32. Amano Y, Takayama M, Amano M, et al.: MRI of cardiac morphology and function after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Am J Roentgenol 2004, 182:523-527.
33. van Dockum WG, Ten Cate FJ, ten Berg JM, et al.: Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004, 43:27-34.
34. Choudhury L, Mahrholdt H, Wagner A, et al.: Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40: 156-2164.
35. Moon JC, Reed E, Sheppard M, et al.: The histological basis of myocardial hyperenhancement by gadolinium cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 43:2260-2264.
36. Moon JCC, McKenna W, McCrohon JA, et al.: Towards clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561-1567.
37. Moon JC, Mundy HF, Lee PJ, et al.: Images in cardiovascular medicine. Myocardial fibrosis in glycogen storage disease type III. Circulation 2003, 107:e47.
38. Moon JC, Sachdev B, Elkington AG, et al.: Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003, 24:2151-2155.
39. Uretsky BF, Thygesen K, Armstrong PW, et al.: Acute coronary findings at autopsy in heart failure patients with sudden death: results from the Assessment of Treatment with Lisinopril And Survival (ATLAS) trial. Circulation 2000, 102:611-616.
40. Moon JC, Perez de Arenaza D, Elkingtion AG, et al.: The pathological basis of Q wave and non-Q wave myocardial infarction - a CMR Study. J Am Coll Cardiol 2004, 554-560.
41. McCrohon JA, Moon JCC, Prasad SK, et al.: Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium enhanced cardiovascular magnetic resonance. Circulation 2003, 108:54-59.
42. Schulz-Menger J, Strohm O, Dietz R, et al.: Visualization of cardiac involvement in patients with systemic sarcoidosis applying contrast-enhanced magnetic resonance imaging. MAGMA 2000, 11:82-83.
43. Serra JJ, Monte GU, Mello ES, et al.: Images in cardiovascular medicine. Cardiac sarcoidosis evaluated by delayed-enhanced magnetic resonance imaging. Circulation 2003, 107:e188-e189.
44. Friedrich MG, Strohm O, Schulz-Menger J, et al.: Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998, 97:1802-1809.
45. Mahrholdt H, Goedecke C, Wagner A, et al.: Multimedia article. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004, 109:1250-1258.
46. Modell B, Khan M, Darlison M: Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000, 355:2051-2052.
47. Westwood M, Anderson LJ, Firmin DN, et al.: A single breath-hold multiecho, T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003, 18:33-39.
48. Anderson LJ, Wonke B, Prescott E, et al.: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002, 360:516-520.
49. Francis JM, Pennell DJ: Treatment of claustrophobia for cardiovascular magnetic resonance: use and effectiveness of mild sedation. J Cardiovasc Magn Reson 2000, 2:139-141.
50. Sparrow P, Plein S, Jones TR, et al.: Tolerance of MRI vs. SPECT myocardial perfusion studies--a patient survey. J Magn Reson Imaging 2004, 19:410-416.